Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock jumped 0.60% on Friday to $1.69 against a previous-day closing price of $1.68. With 4.61 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.73 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.7200 whereas the lowest price it dropped to was $1.6350. The 52-week range on INO shows that it touched its highest point at $4.34 and its lowest point at $1.38 during that stretch. It currently has a 1-year price target of $2.33. Beta for the stock currently stands at 1.07.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INO was down-trending over the past week, with a drop of -11.52%, but this was up by 8.33% over a month. Three-month performance surged to 1.81% while six-month performance fell -19.52%. The stock lost -59.67% in the past year, while it has gained 8.33% so far this year. A look at the trailing 12-month EPS for INO yields -1.48 with Next year EPS estimates of -0.66. For the next quarter, that number is -0.17. This implies an EPS growth rate of -35.60% for this year and 42.30% for next year. EPS is expected to grow by 45.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -7.60%.
Float and Shares Shorts:
At present, 249.35 million INO shares are outstanding with a float of 245.68 million shares on hand for trading. On Oct 13, 2022, short shares totaled 45.57 million, which was 18.27% higher than short shares on Sep 14, 2022. In addition to Dr. Jacqueline E. Shea Ph.D. as the firm’s CEO, Pres & Director, Mr. Peter D. Kies serves as its Chief Financial Officer.
Through their ownership of 46.24% of INO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 31.06% of INO, in contrast to 16.23% held by mutual funds. Shares owned by individuals account for 1.89%. As the largest shareholder in INO with 10.43% of the stake, SSgA Funds Management, Inc. holds 26,025,967 shares worth 26,025,967. A second-largest stockholder of INO, BlackRock Fund Advisors, holds 18,377,706 shares, controlling over 7.37% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in INO, holding 15,032,125 shares or 6.03% stake. With a 10.19% stake in INO, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 25,409,286 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 3.31% of INO stock, is the second-largest Mutual Fund holder. It holds 8,260,428 shares valued at 12.89 million. iShares Russell 2000 ETF holds 2.27% of the stake in INO, owning 5,669,155 shares worth 8.84 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INO since 5 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 1 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With INO analysts setting a high price target of $3.00 and a low target of $2.00, the average target price over the next 12 months is $2.33. Based on these targets, INO could surge 77.51% to reach the target high and rise by 18.34% to reach the target low. Reaching the average price target will result in a growth of 37.87% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. INO will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$1.03 being high and -$1.13 being low. For INO, this leads to a yearly average estimate of -$1.11. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Inovio Pharmaceuticals Inc. surprised analysts by $0.14 when it reported -$0.15 EPS against a consensus estimate of -$0.29. The surprise factor in the prior quarter was -$0.15. Based on analyst estimates, the high estimate for the next quarter is -$0.14 and the low estimate is -$0.19. The average estimate for the next quarter is thus -$0.17.
Summary of Insider Activity:
Insiders traded INO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 27 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 811,617 while 270,506 shares were sold.